Cerenome, Inc. (Nasdaq: CNSY) reported financial results for the third quarter ended September 30, 2026, and provided updates on its CNSide diagnostics platform and REYOBIQ therapeutic development. The company reported total revenue of $0.7 million for the quarter, consisting entirely of net diagnostic revenue from its CNSide CSF Assay Platform. This revenue was derived from approximately $1.55 million in gross billings at list prices, after estimated payer adjustments and price concessions.
Financially, Cerenome reported a net loss of $8.7 million, or $1.14 per share, for the third quarter of 2026. This compares to a net loss of $4.4 million, or $1.03 per share, in the same period a year earlier. The company’s cash, cash equivalents, and investments totaled $4.9 million as of September 30, 2026, a decrease from $8.6 million at the end of the previous quarter. The company noted that in September it closed a senior secured financing facility up to $20 million with royalty-based repayments and subsequently raised $3.8 million under an Equity Distribution Agreement.
On the commercial front, Cerenome expanded its contracted coverage for CNSide through agreements with Medical Mutual, Health Care Service Corporation, and Blue Cross Blue Shield of Michigan. The company also secured in-network agreements with Florida Blue and Aetna. The Aetna agreement, effective November 1, is the first national payer agreement to include both tumor cell enumeration and molecular profiling. The company’s aggregate contracted footprint now represents approximately 190 million covered lives. Additionally, CNSide tests for solid tumors and hematologic malignancies were launched in October, providing DNA and RNA profiling from cerebrospinal fluid.
In its therapeutic pipeline, Cerenome completed enrollment in the Phase 2 ReSPECT-GBM study in recurrent glioblastoma in October. The company expects topline data from this trial in mid-2027. Regarding the REYOBIQ program, interim Phase 1 data from the ReSPECT-LM multi-dose study was presented in November, showing that the first 10 patients treated with repeated doses had no dose-limiting toxicities or treatment discontinuations due to adverse events. The company is also pursuing Medicare reimbursement for CNSide, targeting the first half of 2027, and has a coverage determination pending from Novitas Solutions.
